John Valliant
2020
In 2020, John Valliant earned a total compensation of $7M as Chief Executive Officer at Fusion Pharmaceuticals, a 399% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $311,880 |
|---|---|
| Option Awards | $6,137,543 |
| Salary | $505,124 |
| Other | $28,491 |
| Total | $6,983,038 |
Valliant received $6.1M in option awards, accounting for 88% of the total pay in 2020.
Valliant also received $311.9K in non-equity incentive plan, $505.1K in salary and $28.5K in other compensation.
Rankings
In 2020, John Valliant's compensation ranked 1,392nd out of 13,090 executives tracked by ExecPay. In other words, Valliant earned more than 89.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,392 out of 13,090 | 89th |
Division Manufacturing | 512 out of 5,621 | 91st |
Major group Chemicals And Allied Products | 183 out of 2,254 | 92nd |
Industry group Drugs | 155 out of 1,954 | 92nd |
Industry Biological Products, Except Diagnostic Substances | 45 out of 411 | 89th |
Source: SEC filing on April 27, 2021.
Valliant's colleagues
We found three more compensation records of executives who worked with John Valliant at Fusion Pharmaceuticals in 2020.